

4-Hydroxy-2-methyl-*N*-(2-thiazole)-2*H*-1,2-benzothiazine-3-carboxamide-1,1-dioxide (EX15) and its Cu(II) Complex as New Oxicam Selective Cyclooxygenase-2 Inhibitors

Yousery El-Sayed Sherif,^{a,b,*} Ahmed Abdel-Hamid El-Asmy,^c and Mahmoud Lotfy^{d,e}

^aDepartment of Chemistry, Faculty of Science and Arts, Olla, Taibah University, Kingdom of Saudi Arabia

^bClinical Pharmacology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt

^cDepartment of Chemistry, Faculty of Science, Mansoura University, Mansoura, Egypt

^dMolecular Biology Department, Genetic Engineering and Biotechnology Research Institute, Minufiya University, Sadat City, Minufiya, Egypt

^eDepartment of Applied Medical Sciences, Jouf University, Qurayat, Kingdom of Saudi Arabia

RECEIVED NOVEMBER 21, 2010; REVISED MAY 5, 2011; ACCEPTED JUNE 13, 2011

Abstract. 4-Hydroxy-2-methyl-*N*-(2-thiazole)-2*H*-1,2-benzothiazine-3-carboxamide-1,1-dioxide (EX15) as nonsteroidal antiinflammatory drug (NSAIDs) of oxicam family has been synthesized bearing high selectivity for cyclooxygenase-2 (COX-2) inhibition and high ability to chelate with Cu(II) ions. The EX15-Cu(II) complex, and [Cu(EX15)(OAc)(H₂O)₂], were synthesized and characterized by using elemental analysis, spectral (UV-Vis, IR), conductance, thermal and magnetic studies. Two equations were predicted using quantitative structure activity relationship (QSAR) and regression analysis for the COX-2 and COX-1 selectivity (microsomal assay) with a regression correlation (*R*) close to unity. Two techniques were used to investigate the validity of these equations; macrophage cell line (*in vitro*) selectivity and collagen-adjutant arthritis model in rats (*in vivo*) which showed a significant antioxidant, analgesic and antirheumatic effect for 4-hydroxy-2-methyl-*N*-(2-thiazole)-2*H*-1,2-benzothiazine-3-carboxamide-1,1-dioxide and its Cu(II) complex, [Cu(EX15)(OAc)(H₂O)₂]. (doi: 10.5562/cca1802)

Keywords: Oxicam; metal complexes; analgesic; rheumatoid; anti-inflammatory

INTRODUCTION

Copper induces an inhibition of PGE₂ synthetase leading to a shift in synthesis from the inflammatory PGE₂ to anti-inflammatory PGF series.¹ Free radical scavenging is also mediated by the copper containing superoxide dismutase that can protect joint synovial tissue from hydroxyl and superoxide radical anion O₂^{•-} attack.² The superoxide radical anion O₂^{•-} combining with NO to form peroxynitrate which is an important modulator of cyclooxygenase activity by transformation of arachidonic acid into inflammatory prostaglandin E₂.³ Copper acetate was found more active than hydrocortisone in the carragenan induced paw edema model. The presence of copper chelate *in vivo* was responsible for the observed anti-inflammatory activity.⁴ Similarly, the anti-inflammatory activity of the clinically used antiarthritic agents could be attributed to the formation of copper complex in blood carrying it to the site of inflammation.⁵ Walker and Smith⁶ have separated plas-

ma into different molecular weight fractions and showed that the species of molecular weight below 500 contain active chemicals against rheumatoid arthritis. These fractions are bonded to serum albumin and their activity is due to a mechanism depending on the release of albumin bound copper in the blood which facilitates its availability at the site of inflammation.

Two anti-inflammatory drugs (piroxicam and meloxicam) are available commercially in the market worldwide. The emergence of selective cyclooxygenase-2 enzyme inhibitors for treatment of inflammatory diseases had motivate us to synthesize a new compound having a high selectivity for cyclooxygenase-2 inhibition and ability to form stable complex with Cu(II) ions. The cyclooxygenase-2 selectivity of the new compound is predicted through QSAR using Hyperchem software.⁷ Quantitative observations concerning the anti-inflammatory role of copper drug compounds have been made previously by Sorenson⁴ who reported that copper salts of many acidic anti-inflammatory drugs are more

* Author to whom correspondence should be addressed. (E-mail: youserysherif@gmail.com)

effective for reducing inflammation. Other trace elements which include zinc and gold were used in treatment of rheumatoid arthritis. 4-Hydroxy-2-methyl-*N*-(2-thiazole)-2*H*-1,2-benzothiazine-3-carboxamide-1,1-dioxide (EX15) and its Cu(II) complex with the acetate salt have been selected.

EXPERIMENTAL

All chemicals used were of analytical grade (Sigma, MO, USA) and used as supplied without further purification. Carbon and hydrogen contents were determined at the Microanalytical Unit of Cairo University. Metal analysis was carried out by standard methods.⁸ Molar conductance value of the complex ($c = 10^{-3} \text{ mol dm}^{-3}$) in DMSO was carried out with YSI model 32 Conductivity Bridge. Infrared spectra were recorded using KBr discs on a Mattson 5000 FTIR spectrometer. Electronic spectra were recorded on a UV₂ Unicam UV/Vis spectrophotometer using one cm stoppard silica cells. A Shimadzu TGA-50H thermal analyzer was used to record the TG and DTG curves. The experiments were carried out in dynamic nitrogen (20 mL min^{-1}) with a heating rate of $10 \text{ }^\circ\text{C min}^{-1}$ in the temperature range 25–1000 $^\circ\text{C}$ using platinum crucibles. The sample sizes ranged from 4.65 to 10.52 mg, highly sintered Al_2O_3 was used as a reference.

Synthesis of 4-Hydroxy-2-methyl-*N*-(2-thiazole)-2*H*-1,2-benzothiazine-3-carboxamide-1,1-dioxide (EX15)

EX15 was prepared by amidation method of Manjarrez et al.⁹ as shown in Scheme 1. Brown crystals were precipitated, recrystallized from absolute ethanol and dried in a vacuum desiccator over anhydrous calcium chloride (melting point = 248 $^\circ\text{C}$). The compound is characterized by a mass spectrum which showed a molecular ion peak at $m/z = 337 \text{ (M-1)}^+$.

Preparation of Cu(II)–EX15 Complex

It was prepared by reacting 0.0338 g of EX15 (10 mmol) with 0.02 g of $\text{Cu}_2(\text{CH}_3\text{COO})_4 \cdot 2\text{H}_2\text{O}$ (10 mmol) in 30 mL of water-ethanol mixture (volume ratio = 1 : 1). The mixture was heated for five hrs on a water bath. The resulting green precipitate was washed with ethanol and dried (melting point 276 $^\circ\text{C}$).

Quantitative Structure Activity Relationship (QSAR)

The physicochemical properties (descriptors) of the investigated chemical compounds obtained from Hyperchem version 8 program at the semi-empirical theoretical method using AM1 method.¹⁰ These descriptors include the volume, hydration energy, logarithm of partition coefficient and dipole moment on X–Y directions *dmx* and *dmy*. Multiregression statistical

equations are based on the chemical descriptors data obtained from QSAR investigation.

Semi-empirical Method

The calculation method for commands was placed on the compute menu to semi-empirical quantum mechanics rather than molecular mechanics or *ab initio* quantum mechanics. These calculations solve the Schrödinger equation, with certain approximations, to describe the electron properties of atoms and molecules. In semi-empirical method, the calculations can be simplified by calculating the valence electrons only, neglecting the integrals for certain interactions using standard, non-optimized, and electron orbital basis functions. Experimental parameters eliminate the need to calculate certain quantities and to correct for errors resulting from approximations. This method is applicable and appropriate for all atoms in the periodic table, where the variables are saved in the parameter files. The choice remains until one chooses the molecular mechanics or *ab initio* module. If a file is saved after a semi-empirical calculation, the HIN file will contain the calculated atomic charges.¹¹


AMI

AM1 is a semi-empirical SCF and a developed MNDO method for chemical calculations.¹² It is useful for molecules containing elements from long rows 1 and 2 of the periodic table, but not transition metals. Together with PM3, AM1 is generally the most accurate semi-empirical method included in Hyperchem, it calculates the electronic properties, optimized geometries, total energy, and heat of formation.

Identification the Biological Activity of the Newly Synthesized Compounds

PGE2 Estimation

The new compound, EX15, copper acetate, piroxicam, and Cu (II) - EX15 complex were tested for their anti-inflammatory effects against COX-2 using the *in vitro* macrophage-like cells (P388D1). Cells were washed with fresh media and the tested compounds were added in different concentrations to their respective wells in triplicate and incubated for one hour prior to LPS priming. Then, LPS was added to the wells in a final concentration of 100 ng ml^{-1} . then, it was incubated for one hour. After that, the incubated cells were removed and washed with fresh media. Then, 1.0 ml of media containing platelet-activating factor (10 nM ml^{-1}) and cytochalasin B ($1 \text{ } \mu\text{M ml}^{-1}$) were added. The cells were incubated for four hours and then removed and the supernatant was collected for PGE2 measurement and stored supernatant at $-70 \text{ }^\circ\text{C}$, till use. The assay was performed using the Titerzy1me Prostaglandin PGE ELISA Kit (Sigma). The procedure and instruction of



Scheme 1. Preparation of EX15.

the manufacturer was followed. Samples were read at 405 nm using a microplate reader. The absorbance of the standard (y axis) versus the log concentration of PGE2 for the standard curve was plotted. The PGE2 concentrations were calculated using the standard curve.^{13,14}

Measurement of Joint Inflammation and Pain Tolerance

Thirty six Sprague-Dawley rats (200–250 g) were fed on a standard rat chow and water ad libitum. Animal care and experiments were performed in accordance with NIH guide to the care and use of laboratory animals. The local ethical committee approved the study. The animals were divided into two main groups (non arthritic control and arthritic group). In the arthritic group, all rats had been inoculated by the reagent of collagen adjuvant arthritis into the left paw pad. Rats which developed right paw arthritic manifestations after 45 days were divided into five groups as follow, arthritic control, piroxicam treated, EX15 treated, copper acetate treated and copper complex treated group. The compounds were given orally *via* gastric tube once daily in a dose which calculated according to Paget's table for seven days.¹⁵ Most of the previous compounds are insoluble in water, thus it were suspended in 0.5 % sodium carboxymethyl cellulose (CMC) mg per 200 g of rat weight.¹⁵ This model of Collagen-Adjuvant Arthritis^{16–18} is considered to be a representative of rheumatoid arthritis or ankylosing spondylitis in humans. Collagen II – Freund's adjuvant emulsion (0.1 mL) was injected intradermally into the left hind foot paw-pad of each rat (if no arthritis developed within four weeks, some of the animals were challenged by a second inoculation). After 45 days, the systemic arthritis developed in both hind paws.¹⁹

Pain tolerance measurement right paw pad pressure tolerance was determined for assessment of the analgesic activity of the used drugs, pressure was applied by the analgesimeter (Ugo Basile, Italy) on the rat pad of the right paw. The pressure was increased gradually (a certain number of grams per second until the rat either squeaks or tries to withdraw its limb). The force of pressure was continuously monitored by a pointer moving along a linear scale. Increased pressure tolerance of drug treated rats indicates analgesic activity of the administered drug.²⁰ This measurement of pressure

tolerance was done at the 7th day of drug treatment (45 days after complete Freund's adjuvant injection).

Proximal joint (right ankle) mobilization tolerance (pain scoring) was graded from one to four. Grade one corresponds to tolerance of complete flexion 90°; degrees two, three and four correspond to increasing degree of maltolerance according to a rat hind limb withdrawal, squeaking and when the flexion becomes painful. Degree four corresponds to squeaking with just initiation of flexion. Each of the six non-arthritic, non-treated rats had a score of one.²¹ This measurement of mobilization tolerance was done at the 7th day of drug treatment (52 days after complete Freund's adjuvant injection).

Measurement of Oxidant Stress and Rheumatoid Factor (RF)

Serum malondialdehyde (MDA) as lipid peroxidation was measured by the thiobarbituric acid (TBA) test.²² The sample is treated with TBA at low pH, and a pink chromogen is measured. In the TBA reaction, one molecule of MDA reacts with two molecules of TBA with production of a pink pigment with an absorption maximum at $\lambda = 532\text{--}535\text{ nm}$.²³ Rheumatoid Factor (RF) was estimated using sheep erythrocytes sensitized with rabbit gamma-globulin.

Statistical Analysis

The results are expressed as mean \pm SE. Multiregression analysis (one way ANOVA, Newman-Keuls and *F*-test) was used for correlating physicochemical descriptors to the edema inhibition through QSAR and analysis of the pharmacological data. Mann-Whitney test was for comparison purposes between two groups, whereas Kruskal-Wallis test was used to compare more than two groups. *P* values ≤ 0.05 were considered statistically significant.²⁴

RESULTS AND DISCUSSION

In this work, QSAR equations have been elaborated to select compounds containing oxicam nucleus that are having high selectivity towards COX-2. Previous investigation of Lazer *et al.*²⁵ showed 76 derivatives of 1,2-benzothiazines (Figure 1) in which their biological




Figure 1. Thiozoline derivatives.

activities were monitored at $1.0 \mu\text{g mL}^{-1}$. These chemical compounds were treated individually as NSAID.²⁵ The present QSAR data based on the chemical structures²⁵ that are concerned with physicochemical properties (descriptors) of the investigated chemical compounds. These descriptors were acquired using multi-regression statistical calculations together with the known biological activities. It is noted that the data include equations (Table 1) used for calculating the activity (inhibition percentage for COX-1 and COX-2) of the compounds and focusing on the degree of the validity of the two equations and the most descriptors affecting the biological activity (Table 1). These descriptors include the area (*A*), volume (*V*), hydration energy (HE), logarithm of partition coefficient ($\log P$), high occupied molecular

orbital (HOMO), low unoccupied molecular orbital (LUMO), difference between HOMO and LUMO, dipole moment on X-Y-Z directions (*dmx*, *dmy*, *dmz*), net dipole moment, charge on sulfur [$S_{(1)}$] atom, charge on nitrogen atom (N-CH₃), sum of charges of oxygen atoms on SO₂ [$O_{(7)}$ + $O_{(8)}$], charge on phenolate oxygen atom, [$O_{(9)}$], charge on keto oxygen [$O_{(11)}$], and charge on nitrogen atom [$N_{(12)}$] (Scheme 2).

The degree of validity of the two equations is based on calculating the inhibition percentage of COX-1 and COX-2 at $1.0 \mu\text{g mL}^{-1}$. The data obtained are monitored with the data of Lazer *et al.*,²⁵ one can notice a great coincidence with the previous results.²⁵ From calculations, the most important descriptors affecting the percentage of inhibition of COX-1 and COX-2 are

Table 1. Regression analysis reflecting the validity of the proposed two equations

Equation	<i>F</i> -Value ^(a)	<i>P</i> -Value ^(b)	<i>R</i> ^(c)
At $1.0 \mu\text{g}$ Calcd. % inh. COX-1 = $0.140A + 743HO + 796LU + 700(LU-HO) + 6.40dmx + 6.73dmy - 2.44DMz + 11DM + 0.14\Delta H + 225Q[S(1)] - 1232Q[N(2)] - 2.4Q[O(7)+O(8)] - 99.5Q[O(9)] + 151.8Q[O(11)] - 258.03Q[N(12)] - 1376.62$	13.71	< 0.017	0.88
At $1.0 \mu\text{g}$ Calcd. % inh. COX-2 = $1.17A - 0.518V + 3.53HE + 6.93dmx + 5.93dmy + 7.38dmz - 0.218DM + 0.05\Delta H - 598.9Q[S(1)] - 409.16Q[N(2)] + 3.17[O(7)+O(8)] + 498.3Q[O(11)] + 1494.1$	9.22	< 0.001	0.87

^(a) The degree of freedom.

^(b) The degree of significance.

^(c) Regression coefficient.

the area of the chemical compounds (Table 1). Such foundations are highly coincident with the reported x-ray data.²⁶ The calculated data confirm that the area and volume of the active site of COX-2 are larger than that of COX-1. This fact is the backbone of our thinking in constructing a chemical compound occupying the active site of COX-2 at the expense of COX-1.

The descriptors of seventeen postulated structures (1,2-benzothiazine moiety) are examined (Table 2). Also, their inhibition % on COX-2 and COX-1; EX15 was found the best at 1.0 µg, accordingly its preparation and structure elucidation will be fulfilled. EX15 is characterized by elemental analysis; *Anal. Calcd.* mass fractions of elements, w/%: C = (46.1); H = (3.3), IR spectra: 3400; 3117; 1622; 1601; 1525; 1353 and 1178 [$\nu(\text{OH})$; $\nu(\text{NH})$; $\nu(\text{C}=\text{O})$; $\nu(\text{C}=\text{C})$; $\nu(\text{C}=\text{N})$; $\delta(\text{OH})$ and $\nu(\text{C}-\text{O})$], and the mass spectrum showed a molecular ion peak at $m/z = 337 (\text{M}-1)^+$.

The reaction between Cu (II) acetate and EX15 gave dark green crystals with melting point of 276 °C. The elemental analysis [*Anal. Calcd.* mass fractions of elements, w/%: C = 36.7 (36.2); H = 2.5 (2.6); Cu = 18.2 (18.2)] showed a good agreement with the formula

[Cu (EX15)(OAc)(H₂O)₂]. The complex is stable in air, insoluble in common organic solvents and partially soluble in DMF and DMSO. The IR data reveal that EX15 acts as a monobasic bidentate coordinating through the C=O and the deprotonated C–OH. The coordination was illustrated by the disappearance of the broad band at $\tilde{\nu} = 3400 \text{ cm}^{-1}$ due to $\nu(\text{OH})$ and the observable lower shifts of the $\nu(\text{C}=\text{O})$ and $\nu(\text{C}-\text{O})$ bands, at 1622 and 1178 cm^{-1} in the EX15 spectrum, to 1535 and 1159 cm^{-1} in the complex with complete obscure of $\nu(\text{OH})$ band at 1353 cm^{-1} (Ref. 27). The acetate group acts as a bidentate ligand by the appearance of two bands at 1513 and 1400 cm^{-1} with a difference of 130 cm^{-1} (Ref. 28). The appearance of new bands assigned to $\nu(\text{M}-\text{OH}_2)$ at 580 cm^{-1} and $\nu(\text{M}-\text{O})$ at 440 cm^{-1} supports the suggested coordination sites.²⁹ The $\nu(\text{C}=\text{N})$ observed at 1525 cm^{-1} in the EX15 spectrum still at the same position in the complex spectrum, but with high intensity. Previous work reported its participation.³⁰

The TG thermogram of [Cu(EX15)(OAc)(H₂O)₂] shows a thermal stability till 221 °C. A decomposition stage at 222–276 °C with weight loss of 5.5 (*Anal. Calcd.* 7.3 %) is attributed to the removal of the coordi-

Table 2. The calculated biological activity by the predictable two equations which are concerned with the descriptors of the speculated chemical compounds in Table 4

Compound No.	Speculated molecule Ar	COX-2	COX-1
1	2-Aminobenzothiazolyl	12.21	54.07
2	3-Amino-5-methylthio-1H-1,2,4-triazolyl	37.73	54.01
3	2-Aminopicoline	-41	3.9
4	4-Ethylthiosemicarbazide	32.69	17.74
5	4-Phenylthiosemicarbazide	11.56	17.3
6	5-Aminotetrazolol	-34.8	123
7	4-Aminophenylalcohol	-17.7	6.78
8	2-Aminoacetophenone	3.164	18.65
9	3-Amino-1,2,4-triazole-5-carboxyl	-16.6	1.56
10	2,4-Diamino-1,3,4-thiadiazolol	-4.31	19.81
11	2-(2-Aminophenyl)indole	-20.5	46.25
12	2-Amino-1,3,4-thiadizole	-10.4	17.35
13	2-Amino-4-phenylthiazole	51.52	-73.2
14	7-Amino-4-(trifluoromethyl)coumarin	0.31	38.55
15	4-Hydroxy-2-methyl-N-(2-thiazole)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide	39.3	13.4
16	1-Amino-4-methyl-piperazyl	15.59	31.01
17	5-Amino-1,3,4 thiadiazole-2-thiol	-11.8	19.4

Table 4. Regression analysis reflecting the validity of the proposed two equations

Descriptor	EX15	Melox.	Pirox.
Area	503	531.3	486.4
Volume	826	882.3	882.6
H.E.	-13	-11.81	11.07
Log <i>P</i>	-3	-2.67	-2.51
HOMO	-9.1	-9.06	-8.86
LUMO	-1.2	-1.39	-0.90
HOMO-LUMO	7.92	7.67	7.96
dmx	3.97	4.35	2.29
dmy	-2.4	-2.31	0.60
dmz	-3.9	-4.08	0.37
dm	6.06	6.40	2.39
ΔH	-34	41.42	-43.03
QS1	2.86	2.86	2.86
QN2	-0.72	-0.73	-0.73
QO7 + QO8	1.87	-1.84	-1.86
QO9	-0.26	-0.25	-0.25
QO11	-0.28	-0.25	-0.37
QN12	-0.29	0.00	-0.31

LUMO, lowest unoccupied molecular orbital; HOMO, highest occupied molecular orbital; H.E, hydration energy; Log *P*, Log of calculated octanol-water partition coefficient; dmx (dipole x), dipole moment in *X* direction; dmz, dipole moment in *Z* direction; dm (total dipole), polarization magnitude of dipole moment; ΔH , difference between heats of formation COSMO and vacuum.

sults for complexation of NSAIDs with Cu(II), Zn(II), Cd(II) and Pt(II) ions to produce safer NSAIDs.³⁷⁻³⁹

EX15 and its Cu (II) complex have antioxidant activity as indicated by their lowering effect on serum

Table 6. Influence of copper acetate, piroxicam and [Cu(EX15)(OAc)(H₂O)₂] complex on MDA, rheumatoid factor, pain tolerance, and mobilization tolerance in adjuvant induced rheumatoid arthritis model in rats (M \pm SE)

Group	Dose (expressed in mg 200 g ⁻¹) according to Paget's Table ³⁰	Pain tolerance <i>n</i> = 6	Proximal joint mobilization tolerance <i>n</i> = 6	MDA / nmol mL ⁻¹ <i>n</i> = 6	RF (expressed in IU mL ⁻¹) <i>n</i> = 6
Non-arthritic non-treated	[SCMC] Solvent	1.0 \pm 0.00	1.48 \pm 1.18	2.74 \pm 2.1	178 \pm 2.1 ^(c)
Arthritic non-treated	[SCMC] Solvent	3.9 \pm 0.10 ^{(a),(c)}	3.15 \pm 0.55 ⁺	4.0 \pm 0.39 ^(a)	528 \pm 71.0 ^{(a),(c)}
Cu(Ac) ₂ · 2H ₂ O	0.22	2.5 \pm 0.09 ^{(a),(b),(c)}	2.58 \pm 0.15	2.8 \pm 0.33	385 \pm 21.0 ^{(a),(b),(c)}
Piroxicam	0.36	2.1 \pm 0.12 ^{(a),(b)}	2.07 \pm 0.28 ^(b)	2.8 \pm 0.2	325 \pm 10.0 ^{(a),(b)}
EX15	0.36	2.8 \pm 0.14 ^{(a),(b),(c)}	2.58 \pm 0.6	1.5 \pm 0.42 ^{(a),(b),(c)}	258 \pm 31.0 ^{(a),(b),(c)}
Cu complex	0.96	1.7 \pm 0.09 ^{(a),(b),(c)}	1.67 \pm 0.11 ^(b)	1.8 \pm 0.42 ^{(a),(b),(c)}	190 \pm 9.0 ^{(a),(b),(c)}

n, number of rats; SCMC, 0.5 % sodium carboxymethyl cellulose.

^(a) *P* < 0.001 vs. non-arthritic control.

^(b) *P* < 0.01 vs. arthritic control.

^(c) *P* < 0.01 vs. piroxicam.

Table 5. Cyclooxygenase inhibition power for meloxicam, piroxicam, and EX15 as theoretically determined through our QSAR equations and experimentally as reported earlier.²⁵

	% Inh. COX at 1 μ g drugs			
	COX-2		COX-1	
	Found	Calcd.	Found	Calcd.
Meloxicam	72	69.61	-1	7.12
Piroxicam	58	20.92	10	10.07
EX15	23	39	17	13.4

malonaldehyde level (Table 6) as compared to copper acetate treated groups of rats subjected to collagen adjuvant. The antioxidant activity of piroxicam had been proved by Pipe *et al.*⁴⁰ The mechanism operating for the antioxidant activity of the generated copper acetate complex and piroxicam in the body involves redox cycling at the metal center. The anti-inflammatory improvement of Cu (II) complex was clearly observed from the data obtained when RF was measured in the treated group (Table 6). Copper complex has mobilization tolerance as indicated by its lowering effect as compared to arthritic non treated group of rats subjected to collagen adjuvant. The RF for the Cu (II) complex has lower effect when compared with arthritic non treated group (Table 6).

CONCLUSION

EX15 has been synthesized bearing two advantages; high selectivity for COX-2 inhibition and high ability to chelate with Cu (II) ions. The experimental testing of these compounds (EX15 and the copper complex [Cu(EX15)(OAc)(H₂O)₂]) revealed a significant antioxidant, analgesic and anti-rheumatic effects.

REFERENCES

1. M. E. Elmes, *Lancet* **304** (1974) 1329–1330.
2. D. A. Willoughby, A. R. Moore, and P. R. Colville-Nash, *Lancet* **355** (2000) 646–648.
3. L. M. Landino, B. C. Crews, M. D. Timmons, J. D. Morrow, and L. J. Marnett, *Proc. Nat. Acad. Sci. USA* **24** (1996) 15069–15074.
4. J. R. Sorenson, *J. Med. Chem.* **19** (1976) 135–148.
5. M. Micheloni, P. M. May, and D. R. Williams, *J. Inorg. Nucl. Chem.* **40** (1978) 1209–1219.
6. J. R. Walker, M. J. Smith, A. W. Ford-Hutchinson, and F. J. Billimoria, *Nature* **254** (1975) 444–446.
7. N. M. Hosny, Y. E. Sherif, and A. A. El-Rahman, *J. Coord. Chem.* **61** (2008) 2536–2548.
8. A. I. Vogel, *A Text Book of Quantitative Inorganic Analyses* (2nd edition), Longman, London, 1961.
9. N. Manjarrez and H. I. Perez, *Synth. Commun.* **26** (1996) 1405–1410.
10. Hyperchem Program version 8, available from <http://www.hyperchem.com/homepage>, Windows Hypercube, Inc., USA.
11. H. Kubiny, H. Folkers, and C. Martin, *3D QSAR in Drug Design: Ligand Protein Interactions and Molecular Similarity*, Kluwer Academic Publishers, New York, 1981. p. 138.
12. T. Puzyn, J. Leszczynski, and M. T. D. Cronin, (eds.), *Recent Advances in QSAR Studies: Methods and Applications*, Springer Science + Business Media, 2010, vol. 8, p. 18.
13. M. D. Lister, K. B. Glaser, R. J. Ulevitch, and E. A. Dennis, *J. Biol. Chem.* **264** (1989) 8520–8528.
14. J. Balsinde, *Proc. Nat. Acad. Sci. USA* **91** (1994) 11060–11064.
15. J. E. P. Toman and M. Guy, *Anticonvulsants*, In: *Evaluation of drug activities, Pharmacometrics*, D. R. Laurence, A. L. Bacharach (eds), London and New York, Academic Press 1964, p. 290.
16. D. E. Trentham, A. S. Townes, and A. H. Kang, *J. Exp. Med.* **146** (1977) 857–868.
17. R. Halmdahal, V. Malmstrom, and E. Vuorio, *Ann. Med.* **25** (1993) 251–254.
18. B. H. Waksman, C. M. Pearson, and J. T. Sharp, *J. Immunol.* **85** (1960) 403–417.
19. F. D. Wood, G. M. Pearson, and A. Tanaka, *Int. Arch. Allergy.* **35** (1969) 456–467.
20. L. O. Randall and J. J. Selitto, *Arch. Int. Pharmacodyn Ther.* **111** (1957) 409–419.
21. M. N. Ghosh and H. O. Schild, *Fundamentals of experimental pharmacology*, (1st edition), Scientific Book Agency, Calcutta, India, 1971.
22. V. C. Gavino, J. S. Miller, S. O. Ikharebha, G. E. Milo, and D. G. Cornwall, *J. Lipid Res.* **22** (1981) 763–769.
23. H. H. Draper and M. Hadley, *Methods Enzymol.* **186** (1990) 421–431.
24. H. B. Waynforth, P. A. Flecknell, *Vital statistics and miscellaneous compounds information*, Academic Press, London, 1992.
25. E. S. Lazer, C. K. Miao, C. L. Cywin, and R. Sorcek, *J. Med. Chem.* **40** (1997) 980–989.
26. S. Takeda, K. Misawa, I. Yamamoto, and K. Watanabe, *Drug Metabolism and Disposition* **36** (2008) 1917–1921.
27. A. A. El-Asmy, A. Z. Al-Abdeen, W. M. Abo El-Maaty, and M. M. Mostafa, *J. Spectrochim. Acta* **75** (2010) 1516–1522.
28. A. A. El-Asmy, M. M. Hassanian, M. H. Abdel-Rhman, and I. M. Gabr, *J. Sulfur Chemistry* **31** (2010) 141–151.
29. A. A. El-Asmy, O. A. Al-Gammal, D.A. Saad, and S. E. Ghazy, *J. Molecular Structure* **934** (2009) 9–22.
30. G. Tamasi, F. Serinelli, M. Consumi, M. Consumi, A. Magnani, M. Casolaro, and R. Cini, *J. Inorg. Biochem.* **102** (2008) 1862–1874.
31. A. A. El-Asmy and G. A. A. Al-Hazmi, *Spectrochim. Acta* **71** (2009) 1885–1890.
32. J. L. Masferrer, K. Seibert, B. Zweifel, and P. Needleman, *Proc. Natl. Acad. Sci. USA* **89** (1992) 3917–3921.
33. G. F. Fabiola, L. Damodharan, V. Pattabhi, and K. Nagarajan, *Curr. Sci.* **80** (2001) 26–34.
34. D. Picota, P. J. Loll, and R. M. Garavito, *Nature* **367** (1994) 243–249.
35. S. Ahmad, *Oxidative Stress and Antioxidant Defenses in Biology*, (1st edition.) Chapman & Hall, New York, 1995, p. 356–434.
36. M. B. Grisham, D. J. Heuil, and D. A. Wink, *Am. J. Physiol.* **276** (1999) 315–321.
37. S. C. Dendrinou, G. Tsotsou, L. V. Ekaterinia, A. H. Kortsaris, C. P. Raptopouiou, A. T. Kyriakidis, and D. P. Kessissogiou, *J. Inorg. Biochem.* **71** (1998) 1–6.
38. J. E. Weder, C. T. Dillon, T. W. Hambley, B. J. Kennedy, P. A. Lay, J. R. Biffin, H. L. Regtop, and N. M. Davies, *Coord. Chem. Rev.* **232** (2002) 95–126.
39. A. A. Bekhit, H. T. Y. Fahmy, S. A. F. Rostom, and A. E. A. Bekhit, *Eur. J. Med. Chemistry* **45** (2010) 6027–6038.
40. D. A. Pipe, J. C. MacBrayne, A. W. Graham, and E. U. Allan, *Chim. Ital. Gazz.* **124** (1994) 463.